IP Library Granted Patent US 9,598,437
Granted Patent B2
US 9,598,437 · App. 15/101,224 · Granted Mar 21, 2017

Gamma secretase modulators

Inventors: Mihir B. Mandal (Westfield, NJ); Zhaoning Zhu (Warfield Berkshire, GB)
Assignee: MERCK SHARP & DOHME CORP.
C07D498/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,598,437
App. No.
15/101,224
Granted
Mar 21, 2017
Kind
B2
Abstract

Disclosed herein are compounds of Formula (I) or a pharmaceutically acceptable salt thereof, wherein each of the substituents is given the definition as set forth in the specification and claims. Also disclosed are pharmaceutical compositions containing the compound of Formula (I) and use of the compound in the treatment of neurodegenerative diseases or conditions such as Alzheimer's disease.

Claims (21)

1. A compound of the Formula (I):

or a pharmaceutically acceptable salt thereof,

wherein:

X is a bond, —S—, —S(O) 2 —, —NH—, —O—, —CH 2 —, —C(O) or —CHOH;

R is halogen;

R 1 is hydrogen, —OH or C1-C3 alkyl optionally substituted with 1 to 3 halogen;

n is 0-3;

W is alkyl or alkoxy, wherein the alkyl and alkoxy are optionally substituted with 1 to 3 halogen; and

Y is

 wherein V is —C—or —N—, and Z is halo, alkyl or alkoxy wherein the alkyl or alkoxy is optionally substituted with 1 to 3 halogen.

2. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein n is 2.

3. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R is fluoro.

4. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein Y is:

5. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein Y is selected from the group consisting of:

6. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein Y is:

7. The compound of claim 2 or a pharmaceutically acceptable salt thereof, wherein the R groups that are bound to the phenyl moiety are as shown in Formula (II):

8. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of:

9. The compound of claim 1 or a pharmaceutically acceptable salt thereof, which is:

10. A pharmaceutical composition comprising the compound of claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

11. A pharmaceutical composition comprising the compound of claim 9 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

12. A method of treating Alzheimer's disease comprising administering to a patient in need thereof a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof.

Assignments (2)
MERGER Recorded Aug 8, 2022
From: MERCK SHARP & DOHME CORP.
To: MERCK SHARP & DOHME LLC
Reel/Frame 061102/0145 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 30, 2017
From: MANDAL, MAHIR B.; ZHU, ZHAONING
To: MERCK SHARP & DOHME CORP.
Reel/Frame 041117/0079 →
Continuity (2)
Provisional Application 61911749 · Dec 4, 2013
Related Publication 20160304534A1 · Oct 20, 2016